Windlas Biotech

Windlas Biotech Book Value per Share

The Book Value per Share of Windlas Biotech (WINDLAS.NS) as of Nov 2, 2026 is 275.15 INR. In the previous year, Book Value per Share was 239.59 INR — a change of 14.84% (higher).

Book Value per Share

275.15INR

YoY

14.84%

Last updated:

Book Value per Share of Windlas Biotech is 2026 275.15 INR. Book Value per Share of Windlas Biotech was 2025 239.59 INR. It decreases by 14.84% higher compared to the previous year.

The Windlas Biotech Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2019
91.70 INR
Jan 1, 2020
99.32 INR
Jan 1, 2021
94.32 INR
Jan 1, 2022
187.01 INR
Jan 1, 2023
190.56 INR
Jan 1, 2024
213.14 INR
Jan 1, 2025
239.59 INR
Jan 1, 2026
275.15 INR
The Windlas Biotech Book Value per Share history
YEARBook Value per ShareYoY
275.15INR+14.84%
239.59INR+12.41%
213.14INR+11.85%
190.56INR+1.90%
187.01INR+98.26%
94.32INR-5.03%
99.32INR+8.30%
91.70INR+54.82%
59.23INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Windlas Biotech Stock analysis

What does Windlas Biotech do? Windlas Biotech Ltd. generates revenue through its CDMO services, offering product discovery, development, licensing, and commercial manufacturing for generic and complex generic pharmaceuticals across therapeutic areas like anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies. The company provides formulation development, technology scale-up, and full-scale manufacturing for solid and liquid dosage forms, serving clients in the pharmaceutical industry. Additionally, Windlas markets its own nutraceutical, pharmaceutical, and ayurvedic products through a salesforce and distribution network spanning over 14 states, targeting semi-urban and rural communities. Its manufacturing facilities in Dehradun support both CDMO operations and in-house product production. The company's primary clients for CDMO services are pharmaceutical firms seeking development and manufacturing solutions for generic drugs. These clients benefit from Windlas's capabilities in formulation development, scale-up, and commercial production. The firm's own product line, sold via its distribution network, reaches semi-urban and rural consumers in India, complementing its CDMO business. Manufacturing in Dehradun enables efficient production for both external clients and internal product lines. Windlas Biotech's revenue streams include contract manufacturing for pharmaceutical companies and direct sales of its branded nutraceutical, pharmaceutical, and ayurvedic products. The CDMO segment focuses on complex generics in key therapeutic categories, while the in-house product line targets underserved communities with accessible healthcare solutions. The dual approach leverages the company's manufacturing infrastructure to serve both business-to-business and business-to-consumer markets. Windlas Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Windlas Biotech stock

Book Value per Share of Windlas Biotech is 275.15 INR in 2026.

Book Value per Share of Windlas Biotech changed from 239.59 INR to 275.15 INR, representing a 14.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Windlas Biotech since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Windlas Biotech

All Key Metrics — Windlas Biotech